Not long after cutting its sales forecast for 2025, Valneva has decided to decrease its operational footprint in France by ...

The US FDA has accepted the new drug application (NDA) for BeOne Medicines’ B-cell lymphoma 2 (BCL2) inhibitor, sonrotoclax.

This licensing deal falls under SK's wider ploy to harness the growing promise of radiopharmaceuticals within the oncology ...

Corstasis Therapeutics is to collaborate with CVL on the adoption and integration of the Enbumyst nasal spray into heart ...

With a population of over 670 million people in ASEAN, the total number of patients experiencing rare diseases and conditions ...

The use of real-world evidence (RWE) began gaining traction decades ago, primarily as a response to the limitation around ...

As the US Centers for Medicare and Medicaid Services (CMS) has released the new prices for 15 drugs that have been added to ...

Novartis' Stein site will discontinue solid dose manufacturing in favour of sterile dose and cell & gene therapy production, ...

During the UK’s Autumn Budget, Rachel Reeves has unveiled further technology investments for the UK’s National Health Service ...

The approval marks the first for a targeted treatment in chronic spontaneous urticaria in Europe in over a decad ...

Otsuka Pharmaceutical has accelerated FDA approval for Voyxact to reduce proteinuria in adults with primary IgAN at disease ...

TriLink BioTechnologies senior scientist Dr Cody Palumbo discusses the blockers to manufacturing mRNA-based gene editing ...